FDA approves Tissium’s vascular sealant application

Tissium, a medtech company developing biomorphic programmable polymers for tissue reconstruction, has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant.

Show CommentsClose Comments

Leave a comment